Department of Orthopaedic Surgery and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Zuid-Holland, The Netherlands.
Department of General Practice, Erasmus MC, University Medical Center Rotterdam, Zuid-Holland, The Netherlands.
Scand J Med Sci Sports. 2020 Oct;30(10):1939-1948. doi: 10.1111/sms.13760. Epub 2020 Jul 17.
Achilles tendinopathy (AT) occurs in half of the elite runners. AT is a difficult-to-treat tendon disease, which may progress from new onset to a chronic state. It is unknown how many runners with new-onset AT develop persisting symptoms and which prognostic factors are associated with this course.
To describe how many runners develop persisting symptoms 1 year after onset of reactive AT.
Prospective cohort study.
Runners registering for a Dutch running event (5-42.2 km) were eligible for inclusion. Runners reporting new-onset AT between registration for the running event and 1 month after received a 1-year follow-up questionnaire. The 1-year follow-up questionnaire inquired about persisting symptoms (yes/no), running activity, and metabolic disorders. We calculated the percentage of runners with persisting symptoms and performed a multivariable logistic regression analysis to study the association between potential prognostic factors and persisting symptoms.
Of 1929 participants, 100 runners (5%) reported new-onset AT. A total of 62 runners (62%) filled in the 1-year follow-up questionnaire. Persisting symptoms were reported by 20 runners (32%). A higher running distance per week before new-onset AT was associated with a lower risk of developing persisting symptoms (odds ratio (OR): 0.9, 95% confidence interval (CI): [0.9;1.0]). There was a positive trend toward an association between metabolic disorders and persisting symptoms (OR: 5.7, 95% CI: [0.9;36.2]).
One third of runners develop persisting symptoms 1 year after new-onset AT. Interestingly, a higher running distance per week before new-onset AT potentially lowers the risk of developing persisting symptoms.
阿基里斯腱病（AT）在一半的精英跑者中发生。AT 是一种难以治疗的腱病，可能从新发病例进展为慢性状态。尚不清楚有多少新发 AT 的跑者出现持续症状，以及哪些预后因素与此过程相关。
描述有多少跑者在新发反应性 AT 后 1 年出现持续症状。
前瞻性队列研究。
有资格参加荷兰跑步活动（5-42.2 公里）的跑者均可报名参加。在跑步活动注册和 1 个月后报告新发 AT 的跑者收到了 1 年随访问卷。1 年随访问卷询问了持续症状（是/否）、跑步活动和代谢紊乱情况。我们计算了有持续症状的跑者的百分比，并进行了多变量逻辑回归分析，以研究潜在的预后因素与持续症状之间的关系。
在 1929 名参与者中，有 100 名跑者（5%）报告有新发 AT。共有 62 名跑者（62%）填写了 1 年随访问卷。有 20 名跑者（32%）报告有持续症状。在新发病例 AT 之前，每周跑步的距离越长，发生持续症状的风险越低（比值比（OR）：0.9，95%置信区间（CI）：[0.9；1.0]）。代谢紊乱与持续症状之间存在正相关趋势（OR：5.7，95% CI：[0.9；36.2]）。
三分之一的跑者在新发 AT 后 1 年出现持续症状。有趣的是，在新发病例 AT 之前，每周跑步的距离越长，发生持续症状的风险越低。
